Dr Stock Pick HOT News & Alerts!
_______________________________________
FREE Daily Stock Alerts From DrStockPick.com
_______________________________________
Monday October 5, 2009
DrStockPick.com Stock Report!
Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that FOLOTYN(TM) (pralatrexate injection) is now available for commercial sale in the United States. The U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) on September 24, 2009. This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated. For full prescribing information for FOLOTYN, visit www.folotyn.com. FOLOTYN is the first and only drug approved by the FDA for this indication and represents a new therapeutic option for patients with relapsed or refractory PTCL.
Depomed, Inc. (NASDAQ:DEPO) today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA. The primary endpoint measured pain scores from baseline to the end of a ten-week treatment period using the numerical Likert pain scale.
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm. The SeaGen MARINER trial was a randomized, double-blind phase IIb clinical trial of dacetuzumab or placebo in combination with Rituxan(R) (rituximab) plus ifosfamide, carboplatin and etoposide (R-ICE) chemotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial was closed based upon a recommendation by the Independent Data Monitoring Committee (IDMC) following a pre-specified interim analysis conducted on Friday, October 2, 2009. As a result of the closure, dacetuzumab will no longer be provided to patients enrolled on the trial.
Coventry Health Care, Inc. (NYSE: CVH) announced today that it has signed a definitive agreement to acquire Preferred Health Systems, Inc. (”PHS”), a wholly-owned subsidiary of Via Christi Health System, Inc. PHS, based in Wichita, Kansas, is a commercial health plan serving more than 100,000 commercial group risk members and 20,000 commercial self-funded members. As part of the transaction, Coventry is entering into a long-term provider and customer relationship with Via Christi Health System and its affiliates.
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based producer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced that the Company will present at the 2009 Roth Capital Partners China Conference on Wednesday, October 14, 2009 at 10:00 a.m. Eastern time. The conference is being held at the Fontainebleau Resort in Miami Beach, Fla.
Arrayit Corporation (OTCBB: ARYC), a life sciences and health care technology innovator, announces that on October 1st, 2009, the company deployed its next-generation proteomics platform to customers working in the areas of proteomics and in vitro molecular diagnostics.
No comments:
Post a Comment